Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Diamond Hill Large Cap Strategy Austin Hawley | “Medical products and health care IT services company Solventum was spun off from 3M in April 2024. We believe the company will show improved growth and margins as a standalone entity. The business had previously suffered from underinvestment and market share losses. New management is focused on improving revenue growth. Optimized R&D and product mix should support margin expansion. BSD Analysis: Solventum is healthcare infrastructure spun out of a conglomerate shadow, which clouds perception more than fundamentals. Its products sit in infection prevention, dental, and medical solutions where switching risk is operational, not financial. Investors anchor to spin-off uncertainty and miss how sticky hospital workflows really are. Margin normalization comes from focus and cost discipline rather than heroic growth. Demand tracks procedures and compliance, not consumer sentiment. Balance sheet flexibility matters more than top-line acceleration here. This is healthcare plumbing rebuilding its identity, not a broken business.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Davis Global Fund Danton Goei | “Solventum is a U.S. healthcare business spun out of 3M in April 2024. The company generated over $8 billion in revenue in 2024, most of which came from selling medical-surgical products (mostly for infection prevention and wound care) to hospitals and clinics. Solventum also sells products to dentist offices (e.g., consumables for preventive dental care) as well as coding and transcribing software to hospitals. The business has a long history of attractive growth and margins, but performance weakened under 3M ownership in recent years due to a lack of new product investment and poor integration of acquired businesses, among other factors. The management team, led by industry veteran Bryan Hanson, has deep healthcare experience and a successful collaboration under their belts at a prior healthcare spinoff (Covidien). They are highly focused on reinvigorating earnings growth (back to approximately 4–5% annually) and growing margins. They have also approached the portfolio with fresh eyes, which led to an agreement to sell a non-core purification and filtration business to Thermo Fisher Scientific for an attractive price. Key risks include leverage (which will improve once the company receives proceeds from the sale), as well as the operational risks from standing up independent systems and disentangling from former parent 3M. We bought most of our shares in the heavy selling that accompanied the spinoff post-separation at an attractive valuation of 10x owner earnings. BSD Analysis: Solventum represents a classic spinoff mispricing: a high-quality, under-invested healthcare assets portfolio emerging from a conglomerate with new management and clear self-help levers. Margin recovery should follow renewed product investment, cost rationalization, and divestiture of non-core assets. Its infection-prevention and wound-care franchises benefit from durable demand, while dental and software units provide steady recurring revenue. Shares trade at a discounted ~10× owner earnings despite mid-single-digit organic growth potential and margin expansion runway. Key catalysts include deleveraging, operational stabilization post-separation, and improved capital allocation independent of 3M.” | BEAR | Q2 2025 Jul 18, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
